Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Gastric Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 24 articles: HTML format

Single Articles

October 2025
1. SHITARA K, Rha SY, Wyrwicz L, Oshima T, et al
   Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.
   J Clin Oncol. 2025;43:3152-3159.
   PubMed     Abstract available
   
   
   August 2025
2. ILSON DH
   KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?
   J Clin Oncol. 2025 Aug 19:JCO2501439. doi: 10.1200/JCO-25-01439.
   PubMed    
   
   
   
3. SHITARA K, Lorenzen S, Li J, Bai Y, et al
   Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.
   J Clin Oncol. 2025;43:2502-2514.
   PubMed     Abstract available
   
   
   July 2025
4. SEWASTJANOW-SILVA M, Xiao L, Abdelhakeem A, Pabon CM, et al
   Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma.
   J Clin Oncol. 2025;43:2361-2371.
   PubMed     Abstract available
   
   
   
5. KAWAKAMI H, Kadowaki S, Makiyama A, Tsuda M, et al
   Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
   J Clin Oncol. 2025;43:2184-2195.
   PubMed     Abstract available
   
   
   May 2025
6. SAKAI D, Kadowaki S, Kawabata R, Hara H, et al
   Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.
   J Clin Oncol. 2025 May 23:JCO2401119. doi: 10.1200/JCO.24.01119.
   PubMed     Abstract available
   
   
   January 2025
7. KLEMPNER SJ, Sonbol MB, Wainberg ZA, Uronis HE, et al
   DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.
   J Clin Oncol. 2025;43:339-349.
   PubMed     Abstract available
   
   
   October 2024
8. LI C, Tian Y, Zheng Y, Yuan F, et al
   Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).
   J Clin Oncol. 2024 Oct 9:JCO2400795. doi: 10.1200/JCO.24.00795.
   PubMed     Abstract available
   
   
   
9. PAVLAKIS N, Shitara K, Sjoquist K, Martin A, et al
   INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.
   J Clin Oncol. 2024 Oct 4:JCO2400055. doi: 10.1200/JCO.24.00055.
   PubMed     Abstract available
   
   
   July 2024
10. KANG YK, Kim HD, Yook JH, Park YK, et al
    Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
    J Clin Oncol. 2024 Jul 12:JCO2302167. doi: 10.1200/JCO.23.02167.
    PubMed     Abstract available
    
    
    June 2024
11. SORSCHER S
    Helicobacter pylori and Gastric Cancer Screening.
    J Clin Oncol. 2024 Jun 27:JCO2400509. doi: 10.1200/JCO.24.00509.
    PubMed    
    
    
    
12. HEGEWISCH-BECKER S, Mendez G, Chao J, Nemecek R, et al
    First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
    J Clin Oncol. 2024;42:2080-2093.
    PubMed     Abstract available
    
    
    
13. JANJIGIAN YY, Ajani JA, Moehler M, Shen L, et al
    First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
    J Clin Oncol. 2024;42:2012-2020.
    PubMed     Abstract available
    
    
    
14. BUTT J, Epplein M
    Potent Tool: Helicobacter pylori Treatment to Reduce the Risk of Both Gastric and Colorectal Cancers.
    J Clin Oncol. 2024;42:1865-1867.
    PubMed    
    
    
    March 2024
15. SALANI F, Vivaldi C, Rreka E, Genovesi V, et al
    Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Carcinomatosis: The Need for Clear Answers Through Proper Questions.
    J Clin Oncol. 2024 Mar 14:JCO2302611. doi: 10.1200/JCO.23.02611.
    PubMed    
    
    
    February 2024
16. ZHU M, Yoon HH
    Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
    J Clin Oncol. 2024;42:373-377.
    PubMed    
    
    
    
17. GALLANIS AF, Gamble LA, Samaranayake SG, Lopez R, et al
    Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy.
    J Clin Oncol. 2024;42:421-430.
    PubMed     Abstract available
    
    
    December 2023
18. MOEHLER M, Xiao H, Blum SI, Elimova E, et al
    Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
    J Clin Oncol. 2023;41:5388-5399.
    PubMed     Abstract available
    
    
    November 2023
19. LORENZEN S, Gotze TO, Thuss-Patience P, Biebl M, et al
    Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300975. doi: 10.1200/JCO.23.00975.
    PubMed     Abstract available
    
    
    
20. DEL RIVERO J, Perez K, Kennedy EB, Mittra ES, et al
    Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    J Clin Oncol. 2023;41:5049-5067.
    PubMed     Abstract available
    
    
    October 2023
21. RAU B, Lang H, Koenigsrainer A, Gockel I, et al
    Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.
    J Clin Oncol. 2023 Oct 31:JCO2202867. doi: 10.1200/JCO.22.02867.
    PubMed     Abstract available
    
    
    
22. LEE CK, Kim HS, Jung M, Kim H, et al
    Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.
    J Clin Oncol. 2023 Oct 26:JCO2300971. doi: 10.1200/JCO.23.00971.
    PubMed     Abstract available
    
    
    September 2023
23. KIM CG, Jung M, Kim HS, Lee CK, et al
    Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
    J Clin Oncol. 2023;41:4394-4405.
    PubMed     Abstract available
    
    
    March 2023
24. SHAH MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, et al
    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
    J Clin Oncol. 2023;41:1470-1491.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge.